Pembrolizumab May Be Considered as a First-Line Treatment Option in Non-Squamous NSCLC Even in the Presence of KRAS Mutations
Efficacy of pembrolizumab alone or combined with chemotherapy is solid regardless of KRAS mutations in non-squamous non-small cell lung cancer